Biotech Values

[jbog]

Merck trial of preladenant terminated,

ClinicalTrials.gov shows A Merck (MRK) sponsored study to evaluate the safety and preliminary efficacy of preladenant alone and in combination with pembrolizumab in participants with advanced solid tumors that have not responded to prior therapy was Terminated since "the data did not support study endpoints," according to a post to the ClinicalTrials.gov website last updated on March 5.

Corvus Pharmaceuticals (CRVS) was partnering with Merck on the development on preladenant, according to prior R&D day slides presented by the company.

Read more at:
https://thefly.com/landingPageNews.php?id=2694817


https://clinicaltrials.gov/ct2/show/NCT03099161